7.18

3.46% 0.24

After Hours: 7.16 -0.02 -0.28%

Gyre Therapeutics Inc (GYRE)

Overview News Price History Why GYRE Down? Discussions Forecast

Gyre Therapeutics Inc stock is traded at $7.18, with a volume of 100.53K. It is up +3.46% in the last 24 hours and down -16.99% over the past month. Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Previous Close:

$6.94

Open:

$7.11

24h Volume:

100.53K

Relative Volume:

0.98

Market Cap:

$655.63M

Revenue:

$116.59M

Net Income/Loss:

$9.88M

P/E Ratio:

319.11

EPS:

0.0225

Net Cash Flow:

$-2.40M

1W Performance:

+2.43%

1M Performance:

-16.99%

6M Performance:

-1.51%

1Y Performance:

-24.34%

1-Day Range:

$7.10

$7.34

1-Week Range:

$6.58

$7.34

52-Week Range:

$6.11

$11.78

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name

Gyre Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(858) 567-7770

Address

12770 HIGH BLUFF DRIVE, SAN DIEGO

Employee

618

Twitter

Next Earnings Date

2026-03-16

Latest SEC Filings

GYRE's Discussions on Twitter

Compare GYRE vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GYRE Gyre Therapeutics Inc	7.18	633.72M	116.59M	9.88M	-2.40M	0.0225
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	Jefferies	Buy
Aug-26-25	Initiated	H.C. Wainwright	Buy
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Apr-29-21	Resumed	Stephens	Overweight
Feb-10-21	Initiated	Piper Sandler	Overweight
May-21-20	Initiated	Raymond James	Outperform
Jan-04-19	Initiated	Oppenheimer	Outperform
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy
Feb-09-18	Reiterated	Chardan Capital Markets	Buy
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy
Jun-12-17	Initiated	Chardan Capital Markets	Buy
Jun-06-17	Initiated	Ladenburg Thalmann	Buy
Jun-30-16	Initiated	Rodman & Renshaw	Buy

View All

Gyre Therapeutics Inc Stock (GYRE) Latest News

Mar 24, 2026

Pulmatrix shares dive as privately-held pharma company chooses to merge with Gyre Therapeutics instead - MSN

Mar 24, 2026

Gyre Therapeutics (GYRE) to Release Earnings on Tuesday - MarketBeat

Mar 24, 2026

Mar 23, 2026

Gyre Therapeutics Submits NDA for F351 (Hydronidone) to China CDE for Treatment of Chronic Hepatitis B-Induced Liver Fibrosis - Minichart

Mar 23, 2026

Gyre Therapeutics Files NDA in China for F351 - TipRanks

Mar 23, 2026

Gyre Therapeutics (GYRE) submits China NDA for Hydronidone in CHB liver fibrosis - Stock Titan

Mar 23, 2026

Mar 21, 2026

EV Market: What are analysts price targets for Gyre Therapeutics Inc2026 Drop Watch & Daily Stock Momentum Reports - baoquankhu1.vn

Mar 21, 2026

Mar 19, 2026

Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell - MarketBeat

Mar 19, 2026

Mar 18, 2026

Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2%Time to Sell? - MarketBeat

Mar 18, 2026

China grants priority review to Gyre’s liver fibrosis drug By Investing.com - Investing.com India

Mar 18, 2026

Mar 17, 2026

China grants priority review to Gyre’s liver fibrosis drug - Investing.com

Mar 17, 2026

Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - Bitget

Mar 17, 2026

Aug Intraday: Is Gyre Therapeutics Inc currently under institutional pressureTrade Ideas & Weekly Top Gainers Alerts - baoquankhu1.vn

Mar 17, 2026

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment - The Manila Times

Mar 17, 2026

Gyre Therapeutics, Inc. Announces China?s NMPA Grants Priority Review to the NDA for Hydronidone for CHB-Induced Liver Fibrosis Treatment - marketscreener.com

Mar 17, 2026

Mar 16, 2026

Gyre Therapeutics Faces Operational Risk From Rapid Shifts in Clinical Demand and Market Conditions - The Globe and Mail

Mar 16, 2026

Mar 15, 2026

Gyre Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo

Mar 15, 2026

Mar 14, 2026

Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results - MarketBeat

Mar 14, 2026

Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX) and Gyre Therapeutics (GYRE) - The Globe and Mail

Mar 14, 2026

Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold - MarketBeat

Mar 14, 2026

Mar 13, 2026

Gyre Therapeutics 2025 10-K: Revenue $116.6M, Net Income Per Share Decline - TradingView

Mar 13, 2026

Gyre Therapeutics (NASDAQ: GYRE) grows China fibrosis base, eyes Hydronidone NDAs - Stock Titan

Mar 13, 2026

Analysts Are Bullish on These Healthcare Stocks: Indivior (INDV), Gyre Therapeutics (GYRE) - The Globe and Mail

Mar 13, 2026

Gyre Therapeutics Stock (ISIN: KYG4200L1031) Faces Pressure After Q4 Earnings Miss Amid Pipeline Mom - AD HOC NEWS

Mar 13, 2026

Gyre Therapeutics Sees Stable $100 Million Lung Fibrosis Drug Revenue - marketscreener.com

Mar 13, 2026

Mar 12, 2026

Volatility Watch: Whats Gyre Therapeutics Incs historical returnTrade Performance Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Mar 12, 2026

GNI Group Highlights Fibrosis Revenue Upside and Advances Degrader Pipeline via Gyre and Cullgen - TipRanks

Mar 12, 2026

Gyre Therapeutics (GYRE) Q4 Loss Challenges Bullish Margin Durability Narratives - simplywall.st

Mar 12, 2026